Based on the Lyra Therapeutics Inc stock forecast from 0 analysts, the average analyst target price for Lyra Therapeutics Inc is not available over the next 12 months. Lyra Therapeutics Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Lyra Therapeutics Inc is Bearish, which is based on 2 positive signals and 7 negative signals. At the last closing, Lyra Therapeutics Inc’s stock price was USD 0.09. Lyra Therapeutics Inc’s stock price has changed by -19.21% over the past week, -51.01% over the past month and -98.21% over the last year.
No recent analyst target price found for Lyra Therapeutics Inc
No recent average analyst rating found for Lyra Therapeutics Inc
Company Overview Lyra Therapeutics Inc
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts. Read Less
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designe...Read More
Frequently Asked Questions About Lyra Therapeutics Inc (LYRA) Stock
Stock Target Advisor's fundamental analysis for Lyra Therapeutics Inc's stock is Bearish.
Unfortunately we do not have enough data on LYRA's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on LYRA's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on LYRA's stock to indicate if its overvalued.
The last closing price of LYRA's stock was USD 0.09.
The most recent market capitalization for LYRA is USD 0.01B.
Unfortunately we do not have enough analyst data on LYRA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Lyra Therapeutics Inc's stock.
As per our most recent records Lyra Therapeutics Inc has 88 Employees.
Lyra Therapeutics Inc's registered address is 480 Arsenal Way, Watertown, MA, United States, 02472.
You can get more information about it from Lyra Therapeutics Inc's website at https://lyratherapeutics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Lyra Therapeutics Inc (LYRA) Stock
Stock Target Advisor's fundamental analysis for Lyra Therapeutics Inc's stock is Bearish.
Unfortunately we do not have enough data on LYRA's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on LYRA's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on LYRA's stock to indicate if its overvalued.
The last closing price of LYRA's stock was USD 0.09.
The most recent market capitalization for LYRA is USD 0.01B.
Unfortunately we do not have enough analyst data on LYRA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Lyra Therapeutics Inc's stock.
As per our most recent records Lyra Therapeutics Inc has 88 Employees.
Lyra Therapeutics Inc's registered address is 480 Arsenal Way, Watertown, MA, United States, 02472.
You can get more information about it from Lyra Therapeutics Inc's website at https://lyratherapeutics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for LYRA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
